News and Updates

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

New European Bauhaus Facility Survey

Published on | 4 months ago

Programmes Culture and society Climate, Energy, Mobility Agro-Food, Environment Missions New European Bauhaus

The European Commission has launched a survey for the New European Bauhaus (NEB) Facility for interested parties to contribute to the content of this initiative. The NEB Facility, established in the Horizon Europe 2025-27 Strategic Plan, covers the full cycle of implementation of solutions for neighbourhoods by combining two components: a Research and Innovation part funded by around €120 million per year through Horizon Europe and a roll-out part, with a similar budget ambition as the R&I component, delivered through investments across different EU programmes.

The survey is still open until 17 September 2024.

More information on the New European Bauhaus Facility can be found in this scoping document.

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1484 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.